Waters (NYSE:WAT) Price Target Raised to $536.00

Waters (NYSE:WAT) had its price target boosted by Citigroup from $470.00 to $536.00 in a research note published on Wednesday,Benzinga reports. They currently have a buy rating on the medical instruments supplier’s stock.

A number of other brokerages have also weighed in on WAT. Barclays lifted their target price on Waters from $500.00 to $530.00 and gave the company an “overweight” rating in a research report on Wednesday. The Goldman Sachs Group increased their price target on Waters from $465.00 to $515.00 and gave the stock a “buy” rating in a research report on Monday, September 21st. Deutsche Bank Aktiengesellschaft raised their price target on Waters from $400.00 to $440.00 in a research note on Thursday, October 15th. TD Cowen lifted their price objective on Waters from $515.00 to $530.00 and gave the company a “buy” rating in a report on Wednesday. Finally, HSBC upped their price objective on shares of Waters from $450.00 to $455.00 and gave the stock a “buy” rating in a research note on Tuesday, September 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, Waters has a consensus rating of “Moderate Buy” and a consensus target price of $475.48.

Waters Trading Up 1.1%

Shares of NYSE:WAT traded up $4.84 during trading on Wednesday, reaching $457.92. 695,768 shares of the company were exchanged, compared to its average volume of 995,254. The firm has a market capitalization of $44.99 billion, a PE ratio of 196.53, a P/E/G ratio of 2.62 and a beta of 1.16. The business’s fifty day simple moving average is $434.72 and its 200-day simple moving average is $372.24. Waters has a 12-month low of $282.77 and a 12-month high of $482.28. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.86 and a quick ratio of 1.29.

Waters (NYSE:WAT) last posted its quarterly earnings results on Tuesday, November 3rd. The medical instruments supplier reported $4.10 earnings per share for the quarter, beating the consensus estimate of $4.00 by $0.10. The firm had revenue of $1.77 billion during the quarter, compared to the consensus estimate of $1.75 billion. Waters had a net margin of 3.58% and a return on equity of 11.27%. The company’s revenue was up 120.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.40 earnings per share. On average, research analysts anticipate that Waters will post 14.65 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Westside Investment Management Inc. acquired a new stake in Waters in the third quarter valued at approximately $27,000. Next Level Wealth Planning LLC purchased a new position in Waters in the third quarter worth $29,000. PenderFund Capital Management Ltd. purchased a new position in Waters in the second quarter worth $28,000. First Bancorp Inc ME acquired a new position in shares of Waters during the second quarter worth $30,000. Finally, Caitlin John LLC increased its position in shares of Waters by 43.9% during the second quarter. Caitlin John LLC now owns 82 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 25 shares in the last quarter. Institutional investors own 94.01% of the company’s stock.

More Waters News

Here are the key news stories impacting Waters this week:

• Positive Sentiment: Waters reported $1.77 billion in third-quarter 2026 revenue and raised its full-year guidance, signaling improved expectations for the business. Waters Corporation Reports $1.77 Billion in Third Quarter 2026 Revenue and Raises Full-Year Guidance
• Positive Sentiment: The company agreed to acquire MOBILion Systems, expanding its mass spectrometry and AI-powered proteomics capabilities. The strategic fit could broaden Waters’ technology offering, though the reported item does not quantify the deal’s financial impact. Waters Corporation Acquires MOBILion Systems
• Positive Sentiment: JPMorgan, Barclays, KeyCorp, TD Cowen, Citigroup, and RBC issued reports indicating higher price targets or strong potential appreciation, reinforcing a favorable analyst outlook. JPMorgan price target Barclays outlook KeyCorp outlook TD Cowen price target Citigroup price target RBC outlook

Waters Company Profile

Waters Corporation develops and supplies analytical instruments, software, and consumables used to identify, measure, and characterize chemical and biological materials. Its products include liquid chromatography and mass spectrometry systems, which help customers analyze complex samples.

The company serves pharmaceutical and biotechnology businesses, academic and government laboratories, and customers in fields such as food, environmental testing, and materials science. Waters operates internationally, with customers and operations across multiple regions.

Founded in 1958 by James L.